hospital research foundation grants

• U.S. Department of Health & Human Services

• Virtual Tour
• Staff Directory
• En Español

You are here

Grants & funding.

The National Institutes of Health is the largest public funder of biomedical research in the world. In fiscal year 2022, NIH invested most of its $45 billion appropriations in research seeking to enhance life, and to reduce illness and disability. NIH-funded research has led to breakthroughs and new treatments helping people live longer, healthier lives, and building the research foundation that drives discovery.

three-scientists-goggles-test-tube.jpg

Grants Home Page

NIH’s central resource for grants and funding information.

lab-glassware-with-colorful-liquid-square.jpg

Find Funding

NIH offers funding for many types of grants, contracts, and even programs that help repay loans for researchers.

calendar-page-square.jpg

Grant applications and associated documents (e.g., reference letters) are due by 5:00 PM local time of application organization on the specified due date.

submit-key-red-square.jpg

How to Apply

Instructions for submitting a grant application to NIH and other Public Health Service agencies.

female-researcher-in-lab-square.jpg

About Grants

An orientation to NIH funding, grant programs, how the grants process works, and how to apply.

binder-with-papers-on-office-desk-square.jpg

Policy & Compliance

By accepting a grant award, recipients agree to comply with the requirements in the NIH Grants Policy Statement unless the notice of award states otherwise.

blog-key-blue-square.jpg

Grants News/Blog

News, updates, and blog posts on NIH extramural grant policies, processes, events, and resources.

scientist-flipping-through-report-square.jpg

Explore opportunities at NIH for research and development contract funding.

smiling-female-researcher-square.jpg

Loan Repayment

The NIH Loan Repayment Programs repay up to $50,000 annually of a researcher’s qualified educational debt in return for a commitment to engage in NIH mission-relevant research.

Connect with Us

• More Social Media from NIH

About Grants

Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the  research foundation that drives discovery. Read on for an orientation to NIH funding, grant programs, how the grants process works, and how to apply.

Grants Process Overview

Learn the steps needed for an application to proceed from planning and submission to award and close out. Drill down on each step for guidance that can deepen your understanding of the grants process and help you submit a grant application and manage your grant award. 

Get Started

Before getting started, learn the basics like why it is important to understand the structure of NIH and how we approach grant funding, what types of organizations and people are eligible to apply, what we look for in a research project, and the types of grant programs we offer. Once you have the big picture move on to learn about planning your application.

How to Apply

How to Apply serves as our comprehensive application guide, providing step-by-step instructions to get you through the grant application process, from completing required registrations, finding a funding opportunity to accessing the application forms and instructions, formatting your application, finding due dates and submission policies, and more. 

Application Referral and Review

Once you submit your application to NIH, we assign your application to a specific study section for review and to a specific NIH Institute or Center for funding consideration. After assignment, the application undergoes a two level peer review process. Explore this page to learn more.

Pre-Award and Post-Award Processes

Applications that do well in review begin the pre-award process. Learn what happens during this process and what types of information you will be expected to provide. Once awarded, grantees must follow the requirements in the NIH Grants Policy statement and provide periodic reports to NIH that help NIH monitor the award.

Forms Directory

Essential NIH forms, instructions and format pages you need to apply for, manage, and close out grant awards. 

This page last updated on: March 17, 2017

• Bookmark & Share
• E-mail Updates
• Help Downloading Files
• Privacy Notice
• Accessibility
• National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892
• NIH... Turning Discovery Into Health

Content Type

Topic Categories

• Data Visualization
• Research Briefs
• Email Signup
• Careers & Internships
• Terms & Conditions
• Privacy Policy

Home > Grants > Research Grants

Research Grants

NIHCM Foundation supports innovative, independent, investigator-initiated research with a high potential to inform improvements to the United States health care system.

Grants provide funding for:

• Projects that advance the evidence-base in areas such as health care financing, affordability, delivery, management and/or policy

Application Information

The deadline for submitting Letters of Inquiry for the 2023-2024 funding cycle has passed.

Sign up here to receive information on the 2024-2025 funding cycle.

Events, publications, research, newsletters & more

Monthly newsletter featuring the latest population health trends

All Research Grants & Awards communications

All Journalism Grants & Awards communications

Don't miss our Research Awards.

FEATURED GRANTEE

January 01, 2021 - January 31, 2023

Private Equity Acquisitions of Physician Medical Practices and Implications for Practice Patterns and Costs of Care

Jane Zhu, Oregon Health and Science University

No grantees match these filters, please select a different filter.

January 01, 2024 - December 31, 2024

New Uses of Existing Drugs: The Effects of FDA Regulation and Off-Label Drug Use on Incentives for Pharmaceutical Innovation

Jennifer Kao, University of California, Los Angeles

January 01, 2024 - December 30, 2024

Market, Organizational, and Policy Drivers of Hospital Price Markups for Specialty Drugs

James Robinson, University of California, Berkeley

How Does Interchangeability Impact Biosimilar Adoption?

Pragya Kakani, Weill Cornell Medicine & Luca Maini, Harvard Medical School

June 01, 2024 - August 31, 2025

Private Equity’s Effects on Primary Care Practices Participating in Medicare Advantage

Jane Zhu, Oregon Health & Science University

Spillover Effects of Private Equity Acquisitions of Physician Practices on Local Market Competitors: Implications for Access to Care

Yashaswini Singh, Brown University

A Double-Edged Sword: Evaluating the Role of Telehealth Expansion and Contraction in the US Opioid Crisis

Niam Yaraghi, University of Miami/Brookings Institution

The Effect of AI-Enabled Clinical Software on Health Care Spending and Health Outcomes

Anna Zink, University of Chicago & Hannah Neprash, University of Minnesota

Impact of Capitation Payment Models on Kidney Health Outcomes

Sri Lekha Tummalapalli, Weill Cornell

Evaluating the Effectiveness of the Hospital Price Transparency Rule in Price Reduction

John X Jiang, Michigan State University

February 01, 2023 - June 30, 2024

Evaluating Automatic Enrollment into Marketplace Coverage During the Unwinding of the Medicaid Continuous Coverage Policy: a Two-State Study

Adrianna McIntyre, Harvard University

January 01, 2023 - December 31, 2023

In the Shadows of Trauma: The Economic and Clinical Impact of Childhood Firearm Injuries on Survivors and Family Members

Zirui Song, Harvard Medical School and Massachusetts General Hospital

January 20, 2023 - January 19, 2024

Do Hospital Partnerships with Community-Based Organizations that Address Social Determinants of Health Reduce Hospital Readmission and Mortality?

Yunyu Xiao, Weill Cornell Medicine, Department of Population Health Sciences

March 01, 2023 - August 31, 2024

A State-wide Study of Childbirth-Related Opioid Exposure and Conversion to Postpartum High-Risk Opioid Use

Meredith Matone, University of Pennsylvania and Children’s Hospital of Philadelphia

January 01, 2023 - March 01, 2024

Debunking the Myth that High Drug Prices Accelerate Innovation

Avik Roy, Foundation for Research on Equal Opportunity (FREOPP)

January 01, 2023 - February 29, 2024

Increasing Private Equity Investment in Cancer Care: What is the Effect on Prices and Quality of Care?

Ola Abdelhadi, University of California, Berkeley

January 01, 2023 - June 30, 2023

Can Improving Pharmaceutical Patent Quality Promote Competition and Reduce Drug Prices?

Bhaven N. Sampat, Arizona State University (formerly Columbia University)

January 01, 2023 - June 30, 2024

Increasing Access to Postpartum Mental Health Care via Telehealth: Evidence from Medicaid Coverage of Mental Health Services in Massachusetts

Chanup Jeung, University at Albany, State University of New York (formerly at University of Massachusetts, Amherst)

Understanding Racial and Ethnic Disparities in Timeliness of Diabetes Care

Dan Ly, University of California, Los Angeles & VA Greater Los Angeles

January 01, 2023 - December 31, 2024

The Effect of Hospital Ransomware Attacks on Health Care Delivery and Patient Outcomes

Hannah Neprash, University of Minnesota

June 01, 2023 - May 31, 2024

Improving Competitive Drug Markets by Reviewing Patents

S. Sean Tu, West Virginia University College of Law

The Effects of Physicians’ Financial Transfers from Drug Firms on Prescribing of Physician-Administered Cancer Drugs

Colleen Carey, Cornell University

January 01, 2022 - December 31, 2022

Defining the Digital Divide: Implications for Improving Access to Care

Wendy Brunner, Bassett Medical Center

January 01, 2022 - June 30, 2023

Assessing Postpartum Care Among Medicaid Beneficiaries in an Era of Expanded Access and Telehealth Services

Mark Clapp, Massachusetts General Hospital

February 01, 2022 - June 30, 2023

Marginalized/Minoritized Communities, Health Equity and Medicaid Telehealth Policy

Alison Cuellar, George Mason University

January 01, 2022 - July 01, 2024

Redesigning Payment Policy for Physician-Administered Drugs

Keith Marzilli Ericson, Boston University

Delivering Medicaid Mental Health Services and Supports in Schools

Vinu Ilakkuvan, PoP Health, LLC

Can Medical Practices Afford to Increase Efficiency?

Tim McDonald, Pardee RAND Graduate School

Making Primary Care Count: Intended and Unintended Consequences of the Evaluation & Management Payment Change

January 01, 2022 - December 31, 2023

Vertical Integration of Specialty Physician Practices and the Association with Private Equity Acquisition of Short-Term Acute Care Hospitals

James Roberts, Duke University

Provider Price Strategies and Insurer Counter-Strategies for Infused Drugs in Hospital and Independent Sites of Care

Meals on Wheels Services and Healthcare Utilization Among Frail Older Adults Over Time

Sarah Walsh, Eastern Michigan University

Forum on Traumatic Brain Injury

Katherine Bowman, National Academies of Sciences, Engineering, and Medicine

January 01, 2021 - June 30, 2022

Impact of Medicaid Provider Incentives for Postpartum LARC Provision on Postpartum Contraceptive Use

Jessica Cohen, Harvard University

January 01, 2021 - August 31, 2023

Medically Integrated Dispensing in Oncology

Genevieve Kanter, University of Pennsylvania

February 01, 2021 - May 30, 2022

How Did the Pandemic Change Care for Patients with Chronic Conditions?

May 01, 2021 - July 20, 2022

The Causal Effect of High-Quality Physician-Patient Relationships on Healthcare Costs and Outcomes: Differences by Race/Ethnicity and the Effect of Racial/Ethnic Concordance

Tim Brown, University of California, Berkeley

Price and Quality for Ambulatory Surgery: Differences Between Hospital-Based and Freestanding Centers

Jamie Robinson, University of California, Berkeley

March 01, 2021 - February 28, 2022

Nudging Providers to Curtail Dangerous Opioid Prescribing and Improve the Safety of the Health Care Delivery System

Adam Sacarny, Columbia University

January 01, 2021 - August 31, 2022

Provider Market Power and Adverse Selection in Health Insurance Markets: Evidence from the California Benefits Exchange

Nicholas Tilipman, University of Illinois at Chicago

January 01, 2021 - December 31, 2022

Can Conflict of Interest with the Drug Industry Harm Patients?

Aaron Mitchell, Memorial Sloan Kettering Cancer Center

June 01, 2020 - July 31, 2021

Health and Economic Incidence of the COVID-19 Pandemic

Maria Polyakova, Stanford University

June 01, 2020 - December 31, 2022

The Impact of COVID-19 on Health Care Spending and Practice Patterns

Amol Navathe, University of Pennsylvania

January 01, 2014 - June 30, 2015

The Impact of Payment Reform on Physician Referrals, Patient Flows and Health Care Costs

Bruce Landon, Harvard University

January 01, 2014 - March 15, 2015

Assessing the Impact of Integrated Case Management on Health Services Use and Costs in Medicaid

Gloria Bazzoli, Virginia Commonwealth University

January 01, 2014 - March 31, 2015

Variations in Patient Experience with Tiered Physician Networks

Anna Sinaiko, Harvard University

January 01, 2014 - December 31, 2014

Identifying Winners and Losers Under Proposals to Simplify Drug Plan Choice in Medicare Part D

Jonathan Ketcham, Arizona State University

January 01, 2013 - January 15, 2014

Hospital Acquisition of Physician Practices and Health Care Delivery and Costs

Laurence Baker, Stanford University

January 01, 2013 - October 31, 2013

Evaluating Coverage, Utilization and Access to Care in Medicaid “Early Expander” States Under the Affordable Care Act

Ben Sommers, Harvard University

February 01, 2015 - January 31, 2016

Physician Practice Organization and Health Care Delivery and Costs

January 12, 2015 - January 11, 2016

Do Higher Priced Providers Deliver Higher Quality Care? An Analysis of the Price/Quality Relationship Using HCCI Data

Zack Cooper, Yale University

January 01, 2015 - June 30, 2016

How Are Physician Referral Networks Affected by Physician Practice Ownership and Limited Coverage Network Insurance Products?

January 01, 2015 - April 30, 2016

Physician Practice Styles and Overuse of Healthcare Services

Allison Lipitz-Snyderman, Memorial Sloan Kettering Cancer Center

February 01, 2016 - July 31, 2017

Evaluation of Affordable Care Act Policies to Encourage Accurate Prices for Medicare Services

Miriam Laugesen, Columbia University

January 01, 2016 - October 31, 2017

How Do Patients Rate Experiences with Physicians Who Provide More Low-Value Services?

Prachi Sanghavi, The University of Chicago

January 01, 2016 - December 31, 2016

An Empirical Investigation of Potential Manipulation in the Nursing Home Rating System

Niam Yaraghi, The Brookings Institution

Improving the Effectiveness and Efficiency of High-Risk Care Management through Machine Learning

Ziad Obermeyer, Brigham and Women's Hospital

January 01, 2016 - March 31, 2018

The Prescription Opioid Epidemic: Understanding Its Complications and the Effectiveness of State Policies

Stephen Patrick, Vanderbilt University Medical Center

May 01, 2016 - April 30, 2017

Physician-Driven Overuse of Services for Patients with Advanced Cancer

January 01, 2017 - December 31, 2018

Consumer Directed Health Plan Impact on Low-Value Service Utilization and Spending

Neeraj Sood, University of Southern California

January 01, 2017 - August 31, 2018

eQuality: Improving LGBT, GNC, and DSD Health Through a Comprehensive Medical School Training Program

Susan Sawning, University of Louisville School of Medicine

Patterns and Determinants of Inappropriate Diagnostic Imaging

Gary Young, Northeastern University

Evaluating and Improving Post-Hospitalization Mental Health Follow-Up Care

Kimberley Geissler, University of Massachusetts Amherst

September 01, 2016 - December 31, 2017

Selected Market Failures in Health Care: Analyzing the Scope, Causes, and Potential Solutions

January 01, 2017 - December 31, 2017

Promoting Better Pain Management Outcomes: Precision Decision Support for Opioid Prescription

Ritu Agarwal, University of Maryland

March 01, 2018 - February 28, 2019

Measuring Systemic Overuse in the Privately Insured

Jodi Segal, Johns Hopkins University

January 01, 2018 - June 30, 2019

The Effects of Expanded Access to LARCs on Women’s Outcomes

Jason Lindo, Texas A&M University

January 01, 2018 - March 31, 2019

Addressing Modifiable Healthcare Spending Through Dynamic Modeling Approaches

Julie Lauffenburger, Brigham & Women’s Hospital

January 01, 2018 - December 31, 2019

The Effects of Physician-Hospital Integration on Health Care Spending and Use

Anne Royalty, Indiana University

January 01, 2018 - January 01, 2020

The Impact of Reference Pricing on Hospital-Insurer Bargaining

Christopher Whaley, RAND Corporation

January 01, 2018 - December 31, 2018

Policy Approaches to Insure High Risks

January 01, 2019 - December 31, 2019

Valuing a Cure: Evaluating Different Approaches to Determine a Value-Based Price for a Potential Cure

Principal Investigator: Steven D. Pearson, Institute for Clinical and Economic Review

Very High and Low Residual Spenders in Private Health Insurance Markets

Tom McGuire, Harvard University

January 01, 2019 - September 30, 2020

Persuasion and Welfare in Physician-Industry Relations: Evidence from the Medical Device Industry

Matthew Grennan (currently at UC Berkeley), Wharton School, University of Pennsylvania

January 01, 2019 - March 31, 2021

Effects of Tiered Physician Networks on Health Care Use and Provider Behavior

The Impact of Hospital Consolidation on Care Access, Quality, and Disparities for Low-Income Populations: Evidence from New York Medicaid

Sunita Desai, New York University

January 01, 2019 - December 31, 2024

Why Does the US Overinvest in Technology? The Curious Case of MRI Scanners

January 01, 2019 - March 31, 2022

Impact of ACA Medicaid Expansions on Prenatal Care Utilization and Birth Outcomes

Bassam Dahman, Virginia Commonwealth University

March 01, 2020 - November 30, 2020

Nothing Matters: The Zero-Price Effect in the Individual Insurance Market

Coleman D. Drake, University of Pittsburgh

January 01, 2020 - June 30, 2022

Competitive Dynamics of Physician Referrals in the Era of ACOs

Principal Investigator: Russell J. Funk, University of Minnesota

January 01, 2020 - January 31, 2021

The Impact of Consolidation on Prescription Drug Pricing and Access

Principal Investigator: Josh Feng, University of Utah

June 01, 2020 - August 31, 2022

Geographic Variation in Medicare and Commercial Spending

Principal Investigator: Pierre Thomas Léger, University of Illinois at Chicago

January 06, 2020 - July 31, 2021

Variation Across Health Systems in the Overuse of Healthcare Resources by Older Adults in the United States

Jodi B. Segal, Johns Hopkins University

January 01, 2020 - April 30, 2021

Measuring the Value of Emergency Mental Health Care

Sarah Axeen, University of Southern California

January 01, 2020 - September 30, 2020

Policy Changes that Need to be Made for FQHCs to Utilize Telehealth to Address the Opioid Crisis

Mei Kwong, Center for Connected Health Policy

Improving Postpartum Health through Increased Medicaid Coverage after Childbirth

Maria Steenland, Brown University

January 01, 2020 - July 31, 2022

Bargaining and International Reference Pricing in the Pharmaceutical Industry

Ashvin Gandhi, University of California, Los Angeles

• Contact JAHF
• Tel: 212.832.7788
• Fax: 212.593.4913
• The John A. Hartford Foundation
• 55 East 59th Street 16th Floor New York, NY 10022-1713

Recent grants

Over $724 million invested to improve the care of older adults.

National and state initiatives are creating age-friendly health systems , supporting family caregivers and improving serious illness and end-of-life care . Explore how our funding creates transformative change.

Search for Grants

Results include both active and closed grants.

Priority Area

• Age-Friendly Health Systems
• Family Caregiving
• Serious Illness & End of Life
• Communications & Special Projects

Active Grants

Stay connected, this website uses cookies.

Cookies are used to offer you the most relevant information. Please accept cookies for the best performance.

AHA Research Grant Funding Opportunities

Investigator-initiated research.

For these funding opportunities, applicants initiate the research focus. Qualification for these awards is largely based on the principal investigator’s career stage.

Topic-focused Funding

These programs support specific areas of science deemed critical to achieving our mission and strategic objectives. The AHA co-funds some projects with other organizations to advance common goals.

Data Science Grants

These opportunities fund researchers from anywhere in the world working in the field of data science. Grants support investigators in all career stages, from trainees to senior scientists.

AHA Registry Research

AHA/ASA Quality Programs produce data from millions of patient records in vast databases for advancing scientific research. Investigators can submit proposals to conduct research using this data.

Investigator-initiated Research Opportunities

Topic-focused funding opportunities.

2024 Holidays

• In Memoriam
• Funding opportunities 2024

In This Section

• FDA approvals in lung cancer treatment
• Our Investigators
• Current funded projects
• Research partnerships
• Previous studies
• Current LCMC study
• Publications
• Scientific updates

In keeping with our mission, the LCRF grant program provides funding for research into the prevention, diagnosis, treatment and cure of lung cancer. Our funding mechanisms are designed to fund innovative projects across a variety of diverse topics and to support the careers of talented scientists. To learn about research that has been previously funded by LCRF, please visit the Our Investigators section. Information for investigators seeking funding for research, including an overview of our funding mechanisms and any current requests for proposals, can be found below. For questions about our grants, please contact us at [email protected] .

About Our Grants

Iaslc/lcrf team science award (tsa) on advancing therapies towards curing oncogene-driven lung cancers.

Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the immediate potential to increase survivorship. Given the specific interest in the development of novel therapies that could benefit this group of patients in the relatively near-term, a clinical trial must either be initially incorporated into the project or be an immediate result of the outcome of the research. It is expected that a program of correlative, translational research will be proposed that will enhance the understanding of these oncogenic-driven lung cancers.

With the International Association for the Study of Lung Cancer (IASLC), LCRF encourages applications on a wide variety of topics related to oncogene-driven lung cancer, including but not limited to the following:

• The proposal must include studies in patients and/or patient samples with oncogene-driven lung cancer.
• A proposal that is associated with a clinical trial either as part of the project or planned as a result of the research will be favorably looked upon. Funding from this grant cannot be used to support an ongoing clinical trial. The trial can investigate novel treatment approaches, new therapies (i.e., next generation drugs or agents with novel mechanisms of action, antibody-drug conjugates, etc.), immunotherapy, vaccines, cell therapy, and novel combinations if there is a strong rationale supporting the investigation. The associated clinical trial cannot be an early phase dose-seeking trial. There is a particular interest in investigator-initiated phase IB/II trials.
• The proposal must have a program of 2-3 projects. These projects must be closely integrated and should consist of clinical, basic and/or translational work. Topics of interest can include but are not limited to mechanisms of resistance, studies on the immune landscape and tumor microenvironment, biology and mechanisms of tumor progression, identification of biomarkers to predict sensitivity to specific therapies, methods for optimizing treatment, etc.
• The proposal must have a central, important theme. Projects associated with the proposal must address various aspects of this theme.
• Cancer researchers must be affiliated with an academic/research institution. The research team can include industry partners. The industry partner should support the clinical trial and/or have researchers that have the expertise necessary to the success of the project.

This award provides a maximum of $2,500,000 in funding over a period of four years. Eligible teams must be comprised of independent faculty-level researchers providing complementary interdisciplinary expertise, each of which will make separate but closely integrated contributions to the research being done.

For full details, eligibility criteria, and application instructions, please refer to the request for proposals .

All applications will be evaluated using a two-stage review process that includes review of letters of intent and select full proposals. Only applicants whose LOI is reviewed favorably will be invited to submit a full proposal.

LOIs for this grant will be accepted through March 4, 2024 . Those selected to continue the application process will have until August 12, 2024 to submit their full proposals.

LCRF Leading Edge Research Grant Program

Lung cancer continues to be the number one cause of cancer deaths worldwide, accounting for an estimated 127,070 deaths annually in the United States alone. Despite being the most common cancer killer of both men and women, lung cancer research remains critically underfunded. To help close this gap and improve outcomes, the goal of the LCRF Leading Edge Research Grant Program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. We encourage applications on a wide variety of topics including but not limited to the following:

• Lung cancer biology
• Risk reduction and screening for early detection
• Identification of new biomarkers
• Development of more effective and less toxic therapies including but not limited to targeted and immune-therapies
• Genetic and gene-environment interactions
• Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes
• Mechanisms of sensitivity and resistance to lung cancer therapies
• Bioengineering approaches to understanding and/or treating lung cancer (i.e., theranostics, biomaterials, nanotechnology, controlled-drug release, and gene therapy)
• Supportive measures for people with lung cancer and their families
• Identification of metabolic vulnerabilities in lung cancer

These awards provide a maximum of $150,000 in funding over a period of two years to post-doctoral researchers, clinical fellows, or early- and mid-career investigators with less than 10 years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals .

LOIs for this grant will be accepted through March 4, 2024 . Those selected to continue the application process will have until June 10, 2024 to submit their full proposals.

LCRF Minority Career Development Award (CDA) in Lung Cancer

National Institutes of Health (NIH) funding is considered a prerequisite for establishing independence, academic promotion, recognition as an expert, serving on grant review panels, and leadership roles. Minority applicants are less likely to receive grants, to have the R phases of K01 or K99 awards activated, need more submissions to obtain funding, and often will not resubmit proposals. As minority applicants must overcome systemic and structural barriers due to race, ethnicity, country of origin, socioeconomic status, and/or language, many leave academia which further exacerbates the lack of diversity in Science, Technology, Engineering and Mathematics (STEM) and medical fields. To provide protected time and mentoring to these trainees, we continue to offer the LCRF Minority Career Development Award (CDA) for Lung Cancer for minority postdoctoral/clinical fellows and assistant professors within 10 years of completing their MD and/or PhD degrees to submit proposals.

We encourage applications on a wide variety of topics including but not limited to the following:

These awards provide a maximum of $150,000 in funding over a period of two years to post-doctoral researchers, clinical fellows, or early-career and mid-career investigators within 10 years of receiving their MD and/or PhD. Investigators must be from racial or ethnic groups that are underrepresented in health-related sciences and biomedical research. For complete details, eligibility criteria, and application instructions, please refer to the request for proposals .

LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer

Given the significance and need for early detection of lung cancer and advancements in molecular screening, LCRF continues to offer a funding mechanism to support research projects that facilitate or advance the understanding and characterization of pre-neoplasia or approaches for early detection of lung cancer. Work supported through this mechanism addresses important questions in non-small cell and small cell lung cancer.

This funding mechanism is focused on identifying, characterizing, and developing approaches and techniques that will allow early detection and/or risk reduction of lung cancer and gaining insight into pre-neoplastic processes in the lungs. The ultimate goal is to detect lung cancer at the earliest stages and subsequently increase survival and survivorship. The program is designed to support early-stage researchers and faculty within the first 10 years of their faculty appointment. While this list is not exclusive, general areas of interest include:  

• Identification and characterization of new biomarkers for NSCLC and SCLC
• Liquid biopsy assays and related techniques
• Improvements in risk stratifying patients for screening
• Development of predictive, diagnostic, or prognostic biomarkers
• Genomic and histological approaches to improve early detection in tissue samples
• Novel imaging modalities to identify and risk stratify pre-neoplastic lesions
• Studies of pre-neoplasia and progression to lung neoplasia that may inform prevention strategies
• Development of pathways to increase uptake and utilization of lung cancer screening

These awards provide a maximum of $150,000 in funding over a period of two years to post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than 10 years’ experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals .

LCRF Research Grants on Understanding Resistance in Lung Cancer

In 2024, in partnership with leading patient advocacy organizations, this grant mechanism focuses on understanding the development, prevention, and therapy of resistance by supporting research projects that are identifying, characterizing, treating, or preventing resistance to therapies in lung tumor cells, tissues, mouse models, and/or patients. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship.

We encourage applications on a wide variety of topics related to understanding resistance including:

• Mechanisms of resistance to targeted therapies for oncogene-driven lung cancers
• Biology and mechanisms of drug resistance to lung cancer therapies; i.e. chemotherapy, immunotherapy and radiotherapy
• Novel treatment approaches and new therapies to overcome and/or prevent resistance to lung cancer therapies
• Novel diagnostic approaches to monitor treatment response and relapse

These awards provide a maximum of $150,000 in funding over a period of two years to post-doctoral researchers, clinical fellows, or investigators with less than 10 years of experience since their initial faculty appointment. For full details, eligibility criteria, and application instructions, please refer to the request for proposals .

Mailing List

To receive RFP announcements and other updates related to LCRF funding opportunities, you may subscribe to our mailing list using the form below. You may opt out of these communications at any time.

Heart Failure Research Foundation

The Heart Failure Research Foundation improves the lives of patients by reducing the burden of heart failure through the advancement of scientific knowledge and the promotion of breakthrough research.

Your Generosity at Work

The Heart Failure Research Foundation will find and fund new researchers and cutting-edge research. We are just $15,000 away from opening our first round of Emerging Leader Grants in 2024!  Your philanthropic, tax-deductible gift will provide the resources to accomplish this.

The Heart Failure Research Foundation supports new researchers in all areas related to heart failure. Our Emerging Leaders Grants program is open to all early-stage investigators who have completed their terminal research degree or clinical training and are within 5 years of their first faculty appointment. This program is open to investigators in any field. We will help the next generation of investigators establish successful research careers.

As the Heart Failure Research Foundation launches, our immediate goal is to award 1-2 early-stage investigators with a 1-year grant up to $150,000, with the potential for a renewal for a second year. Our first Emerging Leader class of early career researchers is targeted for 2024.  

Novel approaches in research can struggle to gain a funding foothold. That’s where the Foundation wants to make a difference. We are interested in providing initial funding to established researchers to explore fledgling ideas that have the potential for high reward in the long-term. The proposed project would expect to deliver preliminary data to demonstrate feasaiility and promise for large-scale study. Preference will be given to inter-disciplinary teams.

Transformative Research Grants are a mid-term goal of the Foundation. We hope to release our initial RFP in 2024, and award grants of up to $250,000 annually by 2025.  

Recognizing Our Donors

The Foundation is the philanthropic home for individuals who want to improve the lives of patients through the advancement of heart failure research. Our work is only possible when our donors choose to generously give. 

Diamond Society ($50,000+)

Rich & ann teerlink, sapphire society ($15,000-24,999), robin lewis-gage & family  in memory of harlan lewis & gary gage.

The following individuals have given an annual gift in 2024

Bronze Circle ($1,000-2,499)

Lynne Stevenson

Copper Circle (up to $999)

Gabriel Alugba

John Barnes

Fran & Mark Cardaci  in memory of Louis Naglak

Gerard Goulet in memory of Louis Naglak

Carole Johnson

Miyeon Jung

Harry Lively

David Mailloux  in memory of Edward Strohmayer

Mandeep Mehra

Corinthia Nash

Shsh Hiten Sureshbhai

Randall Starling  in honor of John Barnes

The following individuals gave an annual gift between January 1-December 31, 2023

Platinum Circle ($10,000-14,999)

John Teerlink  in honor of Ann & Rich Teerlink

Gold Circle ($5,000-9,999)

Javed Butler

Silver Circle ($2,500-4,999)

Mark Drazner

Kenneth Margulies

Randall Starling

Camilla Clarke  in honor of Natalie Pierson

James Fang  in honor of Robb Kociol

Michael Givertz

Corrine Jurgens

Angela King  in honor of Natalie Pierson

Colleen McIlvennan  in memory of Patrick D. Rohrer

Orly Vardeny

Amanda Vest

Anonymous in honor of Natalie Pierson

Anonymous in memory of Charles Vargo

Anonymous in memory of Howard Mittler

Abdalla Abdelkader

Kirkwood Adams, Jr.

Nancy Albert

Dionne Barnum  in honor of Natalie Pierson

Kulpreet Barn

Anupam Basuray

Chester Benham  in honor of Dr. Ali Hamid

Cincinnati Ohio Airstream Club in memory of Gerald Fasse

Susan Bionat

Biykem Bozkurt

Leo Buckley

Georges Chahoud

Gwendolyn Claunch

Maria Rosa Costanzo

Pamela Dumaine  in memory of Gerald Fasse

Padmaraj Duwuri

Howard Eisen

Luis Farfan

Michael Felker

Robert Fender  in memory of Gerald Fasse

Mona Fiuzat

Sandy Flanagan  in memory of Gerald Fasse

Kayla Floyd

Janet Gaffney

Juan Garcia Cruz

Maria Giovanna Trivieri

Mazen Hanna

Michael Hanna

Hatem Hassaballa

Karen Hepp Family  in memory of Gerald Fasse

Teresa Hodgkiss

Steven Hollenberg

Jewel King Jewelers  in memory of Gerald Fasse

Andreas Kalogeropoulos

Brian Katona

David Kaufman

Kazuhiko Kido

Michael Kiernan

Michelle Kittleson

Patrick Klocke in memory of Gerald Fasse

Marvin Konstam

Cynthia Kos

Claudine Kuelske  in honor of Melissa Friebis

Sharon LaForest

Ann Laramee

Elizabeth Lee

Gregory Lewis

Sheldon Litwin

Renzo Loyaga-Rendon

Anthony Magalski

Douglas Mann

Kenton Miles  in memory of Gerald Fasse

James Murray

Christopher O'Connor

Anekwe Onwuanyi

Melvin Pierson  in honor of Natalie Pierson

Natalie Pierson

Sean Pinney

Navin Rajagopalan

Josephine Randazzo

Lisa Randolph  in honor of Natalie Pierson

Juan Rodriguez-Escudero

Stephen Rosenthal

Vincent Salvador

Marc Silver

Stanislaw Skaluba

Dolores Smith  in memory of Gerald Fasse

Diane Sockness in memory of Charles Vargo

Neal Stone  in memory of Gerald Fasse

Laura Stott

Nancy Sweitzer

Albert Tallarigo

James Uebel  in memory of Gerald Fasse

Paul Verst  in memory of Gerald Fasse

George Vetrovec

Vytenis Viltrakis  in memory of Gerald Fasse

WB Jones Spring CO Inc  in memory of Gerald Fasse

Suresh Yerra

Natalie Zundel  in honor of John Barnes

Every gift gets us closer to our goal of transforming patient care. Annual donors build the bedrock of our work with their committed, ongoing support each year. They will be recognized at the following levels of giving:

Sustainer  Circle donors commit to monthly gifts using our online donation form. They break their gift into bite-sized chunks that add up to big impact in a year. These donors provide sustainable funding for our programs and receive regular program updates and fewer donation requests. They are recognized at their cumulative Annual Donor Giving Circle above, plus acknowledge in special Sustainers Circle donor listings.

Donors can give in honor of a family member or treatment provider, or remember a loved one, with a gift to Heart Failure Research Foundation. There is a special place on our form to add a dedication. Tribute gifts will be recognized in special listings on our website, and we will send a notification to your honoree or their family.

Leading experts on heart failure care

Our vision is to significantly reduce the burden of heart failure and provide a platform for  collaboration, education, innovation, research, and advocacy to  improve and expand care.

Get in touch

Michael Reese

Research & education foundation.

Providing grants for translational “bench to bedside” research projects converting pure research to results.

Scholarships for diverse students to complete their medical education, and fill the need within their communities.

Connecting underserved patients with comprehensive care and other community support projects.

Community Service

Our vision is excellent care for all patients, regardless of demographic conditions, in the tradition of the former Michael Reese Hospital.

Our Mission

To continue the legacy of Michael Reese Hospital through supporting research, education, and community service through relationships that foster quality health care.

The story of the Foundation begins with Michael Reese Hospital, founded in 1881 to treat all patients regardless of religion, ethnicity or class. As the hospital underwent changes, the Foundation was formed to continue supporting research, education, and the community. While the hospital closed in 2009, the Foundation continues to push forward medical care for patients from different backgrounds.

SmartyTip: Don’t miss any of your deadlines! This is one of the busiest times of the year for applications that are due by June 30 (end of financial year for many funders). Plan ahead now to avoid any rush and submit your application well before its due date.

• The Hospital Research Foundation

There are no rounds available for The Hospital Research Foundation at the moment.

The Hospital Research Foundation Group exists to save lives. We support people in the community by funding vital medical research and patient care activities in hospitals. Our group includes a number of charitable affiliates, providing donors with an opportunity to support a specific area of research or patient care.

Grant Information

• Phone: (08) 8244 1100
• Email: [email protected]

Technical Assistance

• SmartyGrants
• Phone: (03) 9320 6888
• Email: [email protected]
• Technical help guide for applicants

Skip to content

CHOP, Stanford Researchers Identify Protein That Controls CAR T Cell Longevity

Published on Apr 10, 2024

Children's Hospital of Philadelphia

CAR T cell therapy has revolutionized the way certain types of cancer are treated, and the longer those CAR T cells live in a patient’s body, the more effectively they respond to cancer. Now, in a new study, researchers at Children’s Hospital of Philadelphia (CHOP) and Stanford Medicine have found that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers. The findings were published online today by the journal Nature .

T cells are a type of immune cell that recognize and kill pathogens in order to protect the host. Cancer is often able to evade the body’s immune system, but as a result of CAR T cell therapy, a patient’s own T cells can be reprogrammed to recognize and kill these cancer cells, which has led to FDA-approved treatments for certain types of lymphomas and leukemias.

However, fewer than 50% of patients who receive CAR T cell therapy remain cured after a year. One of the reasons for this is that CAR T cells often don’t survive long enough in patients to completely eradicate their cancer. Prior research has demonstrated that patients who are cured through CAR T cell therapy often have CAR T cells that live longer and can more successfully fight cancerous cells.

To determine what helps CAR T cells live longer, researchers wanted to understand the underlying biology behind memory T cells, which are a type of natural T cell whose purpose is to persist and retain function. One protein of interest, FOXO1, which activates genes associated with T cell memory, has previously been studied in mice but remains under-researched in human T cells or CAR T cells.

To learn more about the role of FOXO1 in human CAR T cells, the researchers in this study used CRISPR to delete FOXO1. They found that in the absence of FOXO1, human CAR T cells lose their ability to form a healthy memory cell or protect against cancer in an animal model, supporting the notion that FOXO1 controls memory and antitumor activity.

Researchers then applied methods to force CAR T cells to overexpress FOXO1, which turned on memory genes and enhanced their ability to persist and fight cancer in animal models. In contrast, when the researchers overexpressed a different memory-promoting factor, there was no improvement in CAR T cell activity, suggesting that FOXO1 plays a more unique role in promoting T cell longevity.

Importantly, researchers also found evidence that FOXO1 activity in patient samples correlates with persistence and long-term disease control, thereby implicating FOXO1 in clinical CAR T cell responses.

“These findings may help improve the design of CAR T cell therapies and potentially benefit a wider range of patients,” Weber said. “We are now collaborating with labs at CHOP to analyze CAR T cells from patients with exceptional persistence to identify other proteins like FOXO1 that could be leveraged to improve durability and therapeutic efficacy.”

This study was supported by the National Cancer Institute Immunotherapy Discover and Development grants 1U01CA232361-A1, K08CA23188-01, U01CA260852, and U54CA232568-01; the National Human Genome Research Institute grant K99 HGHG012579 (C.A.L.); the Parker Institute for Cancer Immunotherapy; V Foundation for Cancer Research; Society for Immunotherapy of Cancer Rosenberg Scholar Award; Stand Up 2 Cancer - St. Baldrick's - NCI grant SU2CAACR-DT1113; and the Virginia and D.K. Ludwig Fund for Cancer Research and NCI grant U2C CA233285.

Doan et al, “FOXO1 is a master regulator of memory programming in CAR T cells.” Nature . Online April 10, 2024. DOI: 10.1038/s41586-024-07300-8.

Contact: Ben Leach, The Children’s Hospital of Philadelphia, 267-426-2857 or [email protected]

Safe Movement in the Hospital

Wellness Wednesday

Staying active in the hospital is key to a faster recovery. Regular movement has many benefits, including reducing muscle loss, helping with sleep, improving focus and managing constipation. For people with PD in the hospital, regular movement is important for managing symptoms, preventing falls and minimizing complications.

There is no charge to attend, but registration is required.

Crista Ellis

[email protected]

(828) 352-1079

This is a virtual program, taking place live, using the online Zoom platform. Instructions on joining the webinar are provided after registering.

Upcoming Events

Moving day lexington.

Moving Day is your chance to speak up about Parkinson’s disease and move others to take action.

Moving Day South Alabama

Moving day ventura county, parkinson's connection, personal information.

Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Search for terms

• Advanced Search
• See Studies by Topic
• See Studies on Map
• How to Search
• How to Use Search Results
• How to Find Results of Studies
• How to Read a Study Record

• Learn About Studies
• Other Sites About Studies
• Glossary of Common Site Terms

• Submit Studies to ClinicalTrials.gov PRS
• Why Should I Register and Submit Results?
• FDAAA 801 and the Final Rule
• How to Apply for a PRS Account
• How to Register Your Study
• How to Edit Your Study Record
• How to Submit Your Results
• Frequently Asked Questions
• Support Materials
• Training Materials

• Selected Publications
• Clinical Alerts and Advisories
• Trends, Charts, and Maps
• Downloading Content for Analysis

• ClinicalTrials.gov Background
• About the Results Database
• History, Policies, and Laws
• ClinicalTrials.gov Modernization
• Media/Press Resources
• Linking to This Site
• Terms and Conditions
• Search Results
• Study Record Detail

Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"

• Study Details
• Tabular View
• No Results Posted

Recruitment of volunteers will be competitive. A maximum of 450 children aged 12 to 17 years inclusive will be screened in the study, of which it is planned to include and randomize 300 children who meet the criteria for inclusion in the study and do not have non-inclusion criteria, data on which will be used for subsequent safety and immunogenicity analysis.

Group 1 - 150 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly.

Group 2 - 150 volunteers who will receive a placebo twice with an interval of 21 days intramuscularly.

In case of withdrawal of volunteers from the study, their replacement is not provided.

Inclusion Criteria:

• Volunteers must meet the following inclusion criteria:

Type of participants • Healthy volunteers.

Age at the time of signing the Informed Consent

• from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days).

Paul • Male or female.

Reproductive characteristics

• For girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals).
• For young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals).

Research procedures

• Written Informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial.
• Volunteers who are able to fulfill Protocol requirements (i.e. answer phone calls, fill out a Self-observation Diary, come to control visits).

Non-inclusion criteria:

• Volunteers cannot be included in the study if any of the following criteria are present:

SARS-CoV-2 infection

• A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months.
• History of contacts with confirmed or suspected cases of SARS-CoV-2 infection within 14 days prior to vaccination.
• Positive IgM or IgG to SARS-CoV-2 detected on Screening.
• Positive PCR test for SARS-CoV-2 at Screening / before vaccination.

Diseases or medical conditions

• Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination.
• Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.).
• Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis.
• The axillary temperature at the time of vaccination is more than 37.0 ° C.
• Positive blood test for HIV, syphilis, hepatitis B/C.
• Acute infectious diseases (recovery earl

Exclusion Criteria:

- • Withdrawal of Informed consent by a volunteer and/or a parent of a volunteer;

• The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;
• Availability of inclusion/non-inclusion criteria before vaccination;
• Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;
• The established fact of pregnancy before the second vaccination;
• Taking unauthorized medications (see section 6.2);
• The volunteer's incompetence with the study procedures;
• The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation;
• For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the protocol that may affect the results of the study.
• For Patients and Families
• For Researchers
• For Study Record Managers
• Customer Support
• Accessibility
• Viewers and Players
• Freedom of Information Act
• HHS Vulnerability Disclosure
• U.S. National Library of Medicine
• U.S. National Institutes of Health
• U.S. Department of Health and Human Services